Publications
Impact of Drug Approval Pathways for Paediatric Inflammatory Bowel Disease
Citation
Crowley E, Ma C, Andic M, Feagan BG, Griffiths AM, Jairath V. Impact of Drug Approval Pathways for Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2022 Feb 23;16(2):331-335. doi: 10.1093/ecco-jcc/jjab140. PMID: 34379112.
Abstract
Background and aims: Timely access to approved medications is a priority in paediatric inflammatory bowel disease [IBD]. To date, the timing of drug studies in paediatric IBD has been suboptimal, with most studies conducted long after approval has been granted for adult IBD. This delay in approval leads to extensive off-label prescribing of medications in children, often without clear guidance on optimal dosing.
